- Predictors of treatment switching in the Big Multiple Sclerosis Data Network2023 | First Faculty of Medicine
- Anti-platelet treatment: switching from clopidogrel to prasugrel2012 | Publication without faculty affiliation
- Patients with Fabry Disease after Enzyme Replacement Therapy Dose Reduction Versus Treatment Switch2014 | Central Library of Charles University
- Multiple failures of TNF inhibitors in ankylosing spondylitis patient2019 | Faculty of Medicine in Hradec Králové
- Risk of early relapse following the switch from injectables to oral agents for multiple sclerosis2016 | First Faculty of Medicine
- What we can do for a patient with psoriatic arthritis when TNF inhibitors fail2019 | First Faculty of Medicine
- Biological therapy of migraine: can patients who do not respond to the first anti-CGRP antibody be helped by changing treatment? Case reports from the Headache Center in Thomayer University Hospital, Prague2023 | Third Faculty of Medicine
- Infective endocarditis in 20182018 | Faculty of Medicine in Hradec Králové
- History of viral suppression on combination antiretroviral therapy as a predictor of virological failure after a treatment change2010 | Second Faculty of Medicine, Third Faculty of Medicine
- Long-term Improvement of Fasting Glycaemia after Switching Basal Insulin from NPH to Determir in Children with Type 1 Diabetes: A 1-Year Multicentre Study2008 | Second Faculty of Medicine
- The EGALITY study: a confirmatory, randomized, double-blind study comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, vs. the originator product in patients with moderate-to-severe chronic plaque-type psoriasis2017 | Third Faculty of Medicine
- Long-term effectiveness of recommended boosted protease inhibitor-based antiretroviral therapy in Europe2018 | Faculty of Medicine in Pilsen
- Multiple switches between GP2015, an etanercept biosimilar, with originator product do not impact efficacy, safety and immunogenicity in patients with chronic plaque-type psoriasis: 30-week results from the phase 3, confirmatory EGALITY study2018 | Third Faculty of Medicine
- AURIEL-PsO: a randomized, double-blind phase III equivalence trial to demonstrate the clinical similarity of the proposed biosimilar MSB11022 to reference adalimumab in patients with moderate-to-severe chronic plaque-type psoriasis2020 | Second Faculty of Medicine